Candel Therapeutics, Inc. (CADL)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 6.41 |
| Open | 6.50 |
| Bid | 7.02 x 400 |
| Ask | 7.13 x 100 |
| Day's Range | 6.25 - 7.30 |
| 52 Week Range | 0.66 - 11.40 |
| Volume | |
| Avg. Volume | 5,495,472 |
| Market Cap | 206.9M |
| Beta (5Y Monthly) | 0.92 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
Candel (CADL) rallies 43% as the FDA grants the orphan drug designation to its lead candidate, CAN-2409, for treating non-metastatic pancreatic cancer.
- Simply Wall St.
Retail investors invested in Candel Therapeutics, Inc. (NASDAQ:CADL) up 320% last week, insiders too were rewarded
Key Insights The considerable ownership by retail investors in Candel Therapeutics indicates that they collectively...
- Zacks
Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study
Candel's (CADL) CAN-2409 demonstrates improvements in estimated median overall survival versus the control group in treating borderline resectable pancreatic ductal adenorcarcinoma. The stock rises.
© 2024 Yahoo. All rights reserved.